RESPECT-EPA: Highly Purified EPA Appears to Reduce Risks of CV Events in Japanese CAD Patients on Statins – American College of Cardiology

Use of highly purified eicosapentaenoic acid (EPA) demonstrated borderline statistical significance in reducing the risk of adverse cardiovascular events in Japanese patients with chronic coronary artery disease (CAD) who were also being treated with statins, based on results from the RESPECT-EPA trial presented Nov. 6 during AHA 2022 in Chicago. The trial enrolled 3,844 patients, of whom…

Read the full article here

Related Articles